Rheumatology

Latest News

Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.
Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors

June 26th 2025

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

FDA will not meet original PDUFA data for sebetralstat to treat HAE | Image Credit: Contemporary Pediatrics
FDA will not meet original PDUFA date for sebetralstat to treat HAE

June 16th 2025

Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia

June 9th 2025

FDA accepts navepegritide application to treat children with achondroplasia | Image credit: Contemporary Pediatrics
FDA accepts navepegritide application to treat children with achondroplasia

June 2nd 2025

FDA approves Jivi for patients aged 7 years and older with hemophilia A | Image credit: Contemporary Pediatrics
FDA approves Jivi for patients aged 7 years and older with hemophilia A

May 21st 2025

Latest CME Events & Activities

Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

<12
© 2025 MJH Life Sciences

All rights reserved.